Heart and Kidney Complications in Systemic Sclerosis: The Role of Natriuretic Peptides

Systemic sclerosis patients face overlapping cardiac and renal complications, with natriuretic peptides serving as key biomarkers for assessing cardiorenal involvement.

Pellicano, Chiara et al.·Biomolecules·2025·Moderate EvidenceNarrative Review
RPEP-13007Narrative ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
Moderate Evidence
Sample
N=Not applicable (review)
Participants
Systemic sclerosis patients with cardiorenal involvement

What This Study Found

Cardiorenal involvement is a major driver of morbidity and mortality in systemic sclerosis, with CKD commonly present at PAH diagnosis and independently associated with mortality.

Key Numbers

Reviews troponin, BNP, NT-proBNP, creatinine, cystatin C, NGAL, and galectin-3 as cardiorenal biomarkers in SSc. Type 2 cardiorenal syndrome (CKD from chronic HF) discussed.

How They Did This

Review article examining cardiac and renal complications in systemic sclerosis, focusing on biomarker assessment including natriuretic peptides.

Why This Research Matters

SSc patients often have overlapping organ damage that is difficult to untangle. Recognizing the cardiorenal connection and using appropriate biomarkers can improve risk stratification and treatment timing.

The Bigger Picture

The cardiorenal axis is increasingly recognized as critical in autoimmune diseases. Understanding how heart and kidney damage interact in SSc could improve management of other autoimmune conditions as well.

What This Study Doesn't Tell Us

Review article — does not present new clinical data. SSc is heterogeneous, and cardiorenal involvement varies significantly between patients.

Questions This Raises

  • ?Should SSc patients be routinely screened for subclinical kidney disease at PAH diagnosis?
  • ?Can early intervention targeting both cardiac and renal pathways improve SSc outcomes?

Trust & Context

Key Stat:
CKD independently linked to mortality Chronic kidney disease is common in systemic sclerosis patients with pulmonary arterial hypertension and independently predicts worse outcomes
Evidence Grade:
Review article synthesizing existing literature on cardiorenal involvement in SSc. Provides clinical framework but no new data.
Study Age:
Published in 2025, reflecting current understanding of cardiorenal interactions in systemic sclerosis.
Original Title:
Assessment of Cardiorenal Involvement in Systemic Sclerosis Patients.
Published In:
Biomolecules, 15(9) (2025)
Database ID:
RPEP-13007

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

Why do systemic sclerosis patients develop heart and kidney problems?

SSc causes blood vessel damage and fibrosis (scarring) throughout the body. In the lungs, this leads to pulmonary arterial hypertension, which overloads the right side of the heart. The same vascular damage affects the kidneys, and the two organ systems worsen each other in a vicious cycle.

What role do natriuretic peptides play in SSc monitoring?

BNP and NT-proBNP blood tests help doctors assess how much stress the heart is under. In SSc patients, these biomarkers can help detect cardiac involvement early and guide decisions about treatment intensity.

Read More on RethinkPeptides

Cite This Study

RPEP-13007·https://rethinkpeptides.com/research/RPEP-13007

APA

Pellicano, Chiara; D'Ippolito, Giancarlo; Villa, Annalisa; Martellucci, Ottavio; Basile, Umberto; Carnazzo, Valeria; Basile, Valerio; Rosato, Edoardo; Marino, Mariapaola; Gigante, Antonietta. (2025). Assessment of Cardiorenal Involvement in Systemic Sclerosis Patients.. Biomolecules, 15(9). https://doi.org/10.3390/biom15091297

MLA

Pellicano, Chiara, et al. "Assessment of Cardiorenal Involvement in Systemic Sclerosis Patients.." Biomolecules, 2025. https://doi.org/10.3390/biom15091297

RethinkPeptides

RethinkPeptides Research Database. "Assessment of Cardiorenal Involvement in Systemic Sclerosis ..." RPEP-13007. Retrieved from https://rethinkpeptides.com/research/pellicano-2025-assessment-of-cardiorenal-involvement

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.